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Abstract 
BACKGROUND: 
To understand the poor prognosis of BRAF-mutant advanced colorectal 
cancer (aCRC) patients we examined individual data from patients treated 
with chemotherapy alone in three randomised trials to identify points on the 
treatment pathway where outcomes differ from BRAF-wild-types. 
 
METHODS: 
2530 aCRC patients were assessed from three large randomised trials. End-
points were progression free survival (PFS), response rate (RR), post 
progression survival (P-PS) and overall survival (OS). Treatments included 
first-line oxaliplatin/fluorouracil (OxFU), and second-line irinotecan. Clinicians 
were unaware of BRAF-status 
 
RESULTS 
231 patients (9.1%) had BRAF-mutant tumours. Compared with wild-type, 
BRAF-mutant patients in COIN treated with first-line OxFU had marginally 
inferior RR (34.3% vs 47.5%; adjusted OR=0.58,p=0.020), but similar PFS 
(5.7 vs 6.3 months; adjusted HR=1.14, p=0.26). Following progression on 
first-line chemotherapy, BRAF-mutant patients had markedly shorter P-PS 
(4.2 vs 9.2 months, adjusted HR=1.69,p<0.001). BRAF-mutant status did not 
confer a disadvantage for patients without progression having planned 
chemotherapy-free intervals (OS adjusted HR=0.97, p=0.75). 
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Fewer BRAF-mutant patients received second-line treatment (33% vs 51%, 
p<0.001). However, for those who did, BRAF-mutation was not associated 
with inferior second-line outcomes (RR adjusted OR=0.56, p=0.45; PFS 
adjusted HR=1.01, p=0.93). 
 
CONCLUSIONS 
 
BRAF-mutant aCRC confers a markedly worse prognosis independent of 
associated clinic-pathological features. Chemotherapy does provide 
meaningful improvements in outcome throughout treatment lines. Post-
progression survival is markedly worse and vigilance is required to ensure the 
appropriate delivery of treatment after first- line progression. However, BRAF-
mutant patients may still enjoy treatment breaks when not progressing, and if 
treated with second-line chemotherapy are no less likely to benefit. 
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Introduction 
 
The V600E activating mutation in BRAF (BRAF-mutant) is found in the 
tumours of 8-12% of patients with advanced colorectal cancer (aCRC). These 
patients represent a distinct population with typical clinico-pathological 
features.[1-6] BRAF-mutant aCRC is consistently associated with poor overall 
survival (OS) in case series[4,7,8] and randomised controlled trials (RCTs).[9,10]  
 
The underlying mechanism for this poor outcome is unknown. One 
hypothesis is that BRAF-mutant status confers primary resistance to standard 
chemotherapy or targeted therapies. Retrospective single-centre studies 
describe inferior outcomes with chemotherapy compared with BRAF wild-type 
(BRAF-wt) patients.[4,7,8] However, analysis of a large phase III trial of 
chemotherapy, FOCUS, found that whilst BRAF-mutant status was associated 
with markedly inferior OS, the BRAF-mutant and BRAF-wt patients benefited 
to a similar extent from adding a second drug (oxaliplatin or irinotecan) to 
5FU.[11] Similarly, there is no evidence BRAF-mutant status lessens the 
impact of the addition of bevacizumab to chemotherapy. [12,13]  For only one 
class of drug, anti-EGFR antibodies, has BRAF-mutant status been reported 
to confer lack of benefit,[14] but this finding is inconsistent[10,15,16] and, given the 
modest overall impact of these drugs on survival, does not explain the major 
survival disadvantage seen in BRAF-mutant patients.  
 
Another consistent finding is that BRAF-mutant is associated with a 
greater detriment in OS than in progression-free survival (PFS).  In a pooled 
Commented [JS3]: 3041 words currently 
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analysis of first-line trials, whilst PFS was modestly inferior in BRAF-mutant 
patients (6.2 vs 7.7 months, HR = 1.34 p<0.001), this small difference 
contrasted with very markedly inferior OS (11.4 vs 17.2 months, HR =1.91 
p<0.001).[5]  This raises the question whether BRAF-mutant status confers 
tumour biological changes that lead to accelerated decline following 
progression on therapy, and it is this rather than primary drug resistance that 
drives the poor prognosis. 
 
To investigate this phenomenon, we examine individual patient data 
from three RCTs to identify points on the treatment pathway at which BRAF-
mutant outcomes differ from BRAF-wt patients treated with cytotoxic 
chemotherapy. As cytotoxic agents remain the backbone of contemporary 
treatment of aCRC this analysis is pertinent to modern oncology treatment. 
We compare detailed treatment outcomes in two first-line RCTs with 
oxaliplatin/fluorouracil (OxFU), behaviour during chemotherapy-free intervals 
and following disease progression. We then report patterns of, and outcomes 
with second-line therapy. In order to avoid potential interactions of BRAF 
status with anti-EGFR drugs we focus on patients treated in arms that did not 
include targeted therapies, and at a time when these drugs were not widely 
available in the UK for post-trial use. Potential confounding factors were 
prospectively identified, and analyses adjusted accordingly. BRAF-status was 
unknown to clinicians treating patients in each trial. 
 
 
Patients and Methods: 
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Patient population and treatment: 
 
Individual patient data were obtained from selected arms of three large 
randomised trials, to reflect different clinical uses of standard cytotoxic 
chemotherapy (without targeted therapy) in aCRC (Figure 1).  
 FOCUS (ISRCTN 79877428) was a sequencing trial of first-line and 
planned second-line therapy, and provided a cohort of 430 patients 
receiving single-agent 5FU ahead of planned second-line irinotecan or 
oxaliplatin-based therapy, plus a cohort of 357 randomised to first-line 
doublet (IrFU or OxFU).[17] 
 COIN (ISRCTN 27286448) provided a cohort of 1284 patients 
randomised to first-line oxaliplatin/fluoropyrimidine (OxFp) doublet 
either continuously (Arm A) or with planned chemotherapy-free 
intervals (Arm C).[18,19] 
 PICCOLO (ISRCTN 93248876) provided a cohort of 511 OxFp-
resistant patients treated with second-line irinotecan.[14,20]  
Inclusion criteria for FOCUS and COIN were consistent and both patient 
groups were treated in centres in the UK. Full reports of these studies have 
been published.[14,17-20] National ethical approval and patient consent was 
obtained for all aspects of the clinical and translational research. DNA 
extraction and genotyping for mutations including BRAFV600E was performed 
retrospectively as previously reported.[11,14,16,20] 
 
Statistical analysis 
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Stata was used (Release 12 (2011), StataCorp. College Station, 
Texas). Baseline patient characteristics were compared between BRAF-wt 
patients (with or without other MEK/AKT pathway mutations) and BRAF-
mutant patients using two-tailed T-tests, Wilcoxon rank sum tests (for 
variables with non-normally distributed frequency distributions) and Pearson 
Chi-squared tests (for categorical variables). 
 
In addition to OS (time from randomisation to death from any cause), 
three treatment-related clinical endpoints were used: PFS (time from 
randomisation to first evidence of progression or death); 12-week RECIST 
response rate (RR), and disease control rate (DCR).[21] Finally, we compared 
post-progression survival time (P-PS), defined as time from progression to 
death in those with a progression event.  
 
The prognostic influence of BRAF-mutant status on survival outcomes 
(PFS, P-PS and OS) for first-line trials (FOCUS and COIN), then the second-
line trial (PICCOLO) were analysed using Cox proportional hazards modelling 
and described using hazard ratios (HRs) and 95% confidence intervals (CIs), 
adjusted for factors known to be prognostic or likely to interact with BRAF-
status.  In COIN and FOCUS these were: WHO performance status (2 vs 0/1); 
primary tumour resected (yes vs no); primary tumour location (PTL) (right 
colon vs other); platelet count (< vs ≥ 400,000 /μl); peritoneal metastases 
(present vs absent) and mismatch repair (MMR) status. In PICCOLO, 
adjustment was made for: response to previous therapy; performance status; 
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peritoneal metastases; primary tumour resected and PTL. As these factors 
individually interact with prognosis, adjusted values are reported primarily but 
unadjusted values are provided (Table 2). 
 
Kaplan-Meier (KM) curves were plotted. For response endpoints, odds 
ratios (ORs) and 95% CIs were estimated from logistic regression models for 
the effect of BRAF-mutant status, adjusted for the markers previously 
described. 
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Results: 
BRAF association with clinicopathological variables 
BRAF-mutant status was available for 787/2135 (36.9%) patients in 
FOCUS, 1284/1630 (78.8%) in COIN and 459/511 (89.8%) in PICCOLO 
(Figure 1). The BRAF-mutant prevalence was consistent with published 
values (FOCUS 61/787 [7.8%], COIN 130/1284 [10.1%], PICCOLO 40/459 
[8.7%]). BRAF-mutant patients were more likely than BRAF-wt to be female, 
have right-sided PTL, have peritoneal metastases and nodal metastases, but 
less likely to have lung metastases. BRAF-mutant tumours were more likely to 
have dMMR than BRAF-wt tumours. 8/2530 (0.3%) patients’ tumours had 
dual mutations in both BRAF and KRAS (Table 1). 
 
BRAF status as a prognostic marker for overall survival 
 
BRAF-mutant status was a significant prognostic marker for OS in both 
first-line studies (COIN 9.8 vs 16.6 months, unadjusted HR = 1.78 [1.46-2.17], 
p<0.001; FOCUS 10.9 vs 16.2 months, unadjusted HR=1.55 [1.18-2.04], 
p=0.030)(Table 2). Combining these data [n=2071] gave a median OS of 10.8 
vs 16.4 months (HR=1.49 [1.23-1.80] p<0.001)(Figure 2). 
 
As BRAF-mutant status is associated with clinico-pathological 
characteristics that may interact with survival (Table 1), the impact of these 
were explored in a univariate, then multivariate analysis in pooled data from 
COIN and FOCUS. Significant factors predicting poor OS at univariate testing 
Commented [r4]: Were these MSI also? 
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were BRAF-mutant status, poor performance status, high platelet count, right 
PTL, peritoneal metastases, primary tumour in-situ  and dMMR status; in 
multivariate testing, all factors remained significant other than dMMR status 
(Table 2). 
 
Following adjustment, BRAF-mutant status remained a significant 
prognostic marker in both trials (COIN adjusted HR = 1.51 [1.19-1.91], 
p<0.001; FOCUS adjusted HR=1.44 [1.04-2.00], p=0.030). However given the 
demonstrated prognostic effect of clinical factors associated with BRAF-
mutant status, subsequent analyses are adjusted. 
 
Impact of BRAF status on treatment-related endpoints on first-line 
combination chemotherapy 
 
In contrast to its marked effect on OS, BRAF-mutant status had modest 
or insignificant impact on the first-line PFS and response endpoints.  
 
For patients treated with first-line OxFP in COIN, BRAF-mutant patients 
had an inferior 12-week RR (34.3% vs 47.5%, adjusted OR=0.58 [0.37-0.92], 
p=0.020); however, the differences in DCR and PFS were not significant 
(DCR 59.2% vs 72.0%, adjusted OR=0.76 [0.49-1.20], p=0.24; PFS 5.7 vs. 
6.3 months, adjusted HR=1.14 [0.91-1.42], p=0.26)(Table 3). There was no 
evidence of a differential effect of BRAF status according to the doublet used 
(OxFU or OxCap)(data not shown).  
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Similarly for patients treated with first-line combination chemotherapy in 
FOCUS, there were no differences in efficacy endpoints in BRAF-mutant 
compared with BRAF-wt patients: PFS was 8.2 vs 8.8 months (adjusted 
HR=1.07 [0.69-1.67], p=0.75); RR was 43.7% vs 43.1% (adjusted OR=1.09 
[0.45-2.65], p=0.85); DCR was 68.9% vs 69.9% (adjusted OR=1.01 [0.36-
2.84], p=0.97)(Table 3). There was no evidence of a differential effect of 
BRAF status according to regimen used (OxFU or IrFU, p=0.26).  
 
Impact of BRAF status on post-progression survival 
 
Following progression on first-line combination chemotherapy, BRAF-
mutant patients had markedly reduced P-PS compared with BRAF-wt in both 
first-line trials. In COIN PPS was 4.5 months in BRAF-mutant compared with 
9.6 months in BRAF-wt patients (adjusted HR=1.64 [1.26-2.13], p<0.001). 
Similarly in FOCUS inferior PPS was observed between BRAF-mutant and 
wild-types (3.2 vs 8.1 months; adjusted HR=1.65 [1.03-2.67], p=0.038)(Table 
3). Combining this data PPS was inferior in the BRAF-mutant compared with 
the BRAF-wt group (4.2 vs 9.2 months, HR=1.62 [1.29-2.04], p<0.001)(Figure 
3).  These marked differences were independent of first-line treatment 
received (in COIN, OxFU vs OxCap p=0.57, in FOCUS OxFU vs IrFU 
p=0.91)(data not shown).  
 
When other prognostic factors were tested in a combined multivariate 
model, a significant negative effect on P-PS was seen after first-line 
chemotherapy for peritoneal metastases and dMMR status (peritoneal 
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metastases HR=1.39, p<0.0001; dMMR HR=1.38, p=0.025). However the 
negative prognostic impact of peritoneal metastases and dMMR appears 
limited to the BRAF-wt population, and neither factor impacted further on the 
poor P-PS seen in BRAF-mutant patients (interaction p= 0.005 and p=0.05 
respectively), showing that it is the BRAF-mutation driving the observed poor 
outcomes (Supplementary Table 1). 
 
Impact of BRAF status on salvage therapy 
 
To explore the mechanism for inferior first-line P-PS in BRAF-mutant 
patients, we studied uptake of post-progression therapies and survival 
outcomes of those who received second-line treatment, compared to those 
who did not. 
 
In COIN, BRAF-mutant patients were less likely to receive second-line 
therapy after first-line progression (33% vs. 51%, p=0.0002). Similarly, after 
completion of the FOCUS plan, which for all patients included two drugs (FU 
and either oxaliplatin or irinotecan, given over 1 or 2 ‘lines’), 123/401 (30.7%) 
BRAF-wt and 3/29 (10.3%) BRAF-mutant patients received subsequent 
salvage therapy (p=0.020)(data not shown).   
 
The duration of second-line therapy (regimens including FU-based, Ir-
based, oxaliplatin-based, cetuximab and bevacizumab) for those who 
received it, was unaffected by BRAF-mutant status (COIN p=0.55, FOCUS 
p=0.18). The only exception was the subgroup of FOCUS patients 
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randomised to receive IrFU after progression on FU alone, where BRAF-
mutant status was associated with shorter treatment duration (p=0.019)(data 
not shown).  
 
OS was improved in COIN for those who received subsequent second-
line chemotherapy compared with those without, regardless of BRAF status 
(BRAF-mut 16.1 vs 7.8 months [HR=0.56, p=0.005]; BRAF-wt 21.1 vs 11.6 
months [HR=0.45, p<0.001]; interaction p=0.66)(Figure 4). However BRAF-
mutant patients had worse OS whether treated with second line 
chemotherapy, (HR=1.91[1.36-2.69], p<0.001), or not (HR=1.44 [1.12-1.84], 
p=0.004), compared with wild-types(data not shown). 
 
Impact of chemotherapy-free intervals in BRAF-mutant patients  
 
In contrast to the higher death rate after failure of first-line 
chemotherapy, there was no evidence that BRAF-mutant patients fare less 
well with a planned treatment break when first-line treatment has not yet 
failed. COIN, which compared continuous or intermittent chemotherapy 
strategies, found that intermittent chemotherapy was non-inferior for OS 
(adjusted HR=1.04 [0.98–1.10], p=0.16);[19] in BRAF-mutant patients this was 
also the case (adjusted HR=0.97 [0.80–1.17], p=0.75) (Supplementary Figure 
1). 
 
Overall in COIN, progression events in patients during chemotherapy 
breaks led to shorter PFS (adjusted HR=1.27 [1.21–1.33], p<0.001).[19]  
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Interestingly, however, BRAF-mutant patients were the only molecular sub-
group not to have a PFS disadvantage with intermittent chemotherapy (BRAF-
mutant PFS adjusted HR=1.09 [0.91–1.31], p=0.33; BRAF-wt PFS adjusted 
HR=1.29 [1.21–1.37], p<0.001; interaction p=0.14)(Supplementary Figure 1).   
 
Outcomes with single agent chemotherapy 
 
We additionally examined the impact of BRAF-status on outcomes with 
single agent chemotherapy, often utilised in combination with targeted agents. 
With first-line single-agent 5FU in FOCUS, PFS was similar in BRAF-mutant 
and BRAF-wt patients (6.5 vs 6.7 months; adjusted HR=0.96 [0.60-1.52], 
p=0.30); RR was 17.2% vs 21.7% (adjusted OR=0.54 [0.17,1.72], p=0.30); 
DCR 48.3% vs 60.6% (adjusted OR=0.72 [0.27-1.94], p=0.52)(Supplementary 
Table 2).  
 
Following progression on single-agent 5FU, PPS was reduced in the 
BRAF-mutant group (3.5 vs 9.3 months; adjusted HR = 2.19[1.30-
3.69],p=0.003) (Supplementary Table 2), again with a lower uptake of second 
line therapies (39.3% vs 58.4%, p=0.048). 
 
The impact of BRAF-status on outcomes for 459 patients treated with 
second-line Ir were examined in the PICCOLO trial. Whilst OS was shorter for 
BRAF-mutant patients compared with wild-types, the difference did not reach 
statistical significance: 6.7 vs 10.2 months (adjusted HR=1.21 [0.84-1.76], 
p=0.31)(Supplementary Table 2 and Supplementary Figure 2). 
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Similar to first line data efficacy data, and subsequent outcomes with 
salvage therapy, there were no significant differences in the treatment-related 
endpoints between BRAF-mutant to BRAF-wt patients: PFS was 3.5 vs 4.0 
months (adjusted HR=1.01 [0.69-1.49], p=0.93); RR was 5.0% vs. 8.1% 
(adjusted OR=0.56 [0.13-2.49], p=0.45); DCR was 42.5% vs. 47.7% (adjusted 
OR=0.82[0.41-1.62], p=0.57)(Supplementary Table 2).  
 
In PICCOLO, P-PS was 5.9 months in BRAF-mutant patients, 6.5 
months in BRAF-wt patients (adjusted HR=1.28 [0.81-2.01], p=0.29) 
(Supplementary Table 2). The only factor predicting shorter P-PS in 
multivariate testing was the presence of peritoneal metastases 
(HR=1.34[1.04-1.75], p=0.026)(data not shown). 
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Discussion 
 
This is the largest and most comprehensive clinical series assessing 
the outcomes of BRAF-mutant patients treated with chemotherapy at different 
points of the aCRC pathway. The poor prognosis of BRAF-mutant aCRC 
compared with wild-types was confirmed. The novel and most striking findings 
are that this poor outlook is not driven by chemoresistance, and that the point 
at which outcomes markedly diverge from wild-types is following progression 
on first-line chemotherapy. Results were consistent between FOCUS and 
COIN, independent of chemotherapy strategy and other standard prognostic 
factors.  
 
The poor outcomes advanced BRAF-mutant aCRC are well described, 
but these cancers are associated with specific clinico-pathological features: 
older age, proximal primary tumour, high grade, deficient MMR, mucinous 
histology and peritoneal and lymph node metastases,[5-10] most of which 
interact with prognosis. In a careful multivariate analysis in a large, 
prospectively gathered cohort, BRAF mutation still conferred a worse 
prognosis and is not simply attributable to associated clinico-pathological 
features.  
 
We then examined at what points in the aCRC pathway did this poor 
outcome manifest, and have convincingly demonstrated it is not due to 
intrinsic chemo-resistance. There was no difference in the adjusted PFS 
between BRAF-mutant and wild-type patients on first line OxFP in COIN and 
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in any FOCUS strategies. Furthermore, there was no difference in efficacy 
endpoints in patients treated with second-line irinotecan monotherapy by 
BRAF-mutant status in PICCOLO, or in the relative benefit of second-line 
therapy after failure on COIN treatment. Thus, chemotherapy throughout the 
lines of therapy provides equivalent degrees of disease modification 
irrespective of BRAF-status. However the absolute impact is less due to the 
poor overall outcome; highlighted by the worse overall survival of BRAF-
patients receiving further chemotherapy in COIN, compared to wild-types. 
Thus, the equivalent absolute outcome benefits (PFS and DCR) on first-line 
OxFP are noteworthy.  
 
Other studies suggest that oxaliplatin may be particularly important in 
BRAF-mutant patients. Biomarker analysis from MOSAIC (testing the addition 
of oxaliplatin to FP in adjuvant CRC) reported that the OS HR for OxFP vs FP 
alone was 0.55 in the BRAF-mutants, and 0.93 in wild-types. The 3 year DFS, 
5 year OS and 10 year OS absolute differences for the addition of oxaliplatin 
were 16.4%, 9.5% and 10.1% respectively compared with only 2.4, 1% and 
1.9 in wild type patients. In the TRIBE study (FOLFOXIRI plus bevacizumab 
vs FOLFIRI plus bevacizumab in the first-line treatment of aCRC), PFS HR for 
the addition of oxaliplatin to FOLFIRI/Bevacizumab in BRAF-mutant patients 
was 0.54, compared with 0.85 in the RAS/RAF wild-types; the ORs for 
response was 1.82 and 1.17 respectively. 
 
BRAF-mutant patients have markedly worse survival after progression 
on first-line treatment, with important implications for patient management. 
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Prompt initiation of second-line treatment appears to slightly ameliorate this 
risk: in COIN BRAF-mutant patients without second-line treatment 
demonstrated rapid decline after first line therapy failure. This finding was 
independent of poor performance status. However in the first-line trials, fewer 
BRAF-mut patients proceeded to receive second-line chemotherapy. It is 
important emphasise that treating physicians were unaware of BRAF-status 
therefore this finding is not due to selection bias. Extra vigilance is therefore 
needed in BRAF-mutant patients to detect progression and rapidly institute 
second-line therapy as appropriate given that such treatment significantly 
improves overall survival albeit with less absolute benefit than in wild-type 
patients.  
 
Some may view the observed rapid decline after first-line progression 
and risk of being unable to deliver second-line treatment as a strong argument 
for using upfront FOLFOXIRI-based regimens in BRAF-mutant patients. 
Indeed, a potential criticism of the current study is that we did not investigate 
outcomes with triplet treatment. However the current data remain highly 
pertinent given that many patients with advanced cancer are not fit enough to 
receive this treatment in spite of being well enough to potentially benefit from 
sequential chemotherapy.  
 
Equally importantly for routine practice, we found that whilst BRAF-
mutant patients are at risk of accelerated decline after progression, this does 
not mean that they cannot safely enjoy an intermittent strategy including 
periods off chemotherapy when treatment has not yet failed. Thus such 
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patients with disease control can be appropriately counselled about the safety 
of chemotherapy free intervals.  
 
These data allow the development of two non-mutually exclusive hypotheses 
to explain the inferior survival of BRAF-mutant patients. Firstly these patients 
may simply have a worse prognosis from initiation of their treatment 
programme and that equivalent PFS and DCR reflects enhanced relative 
benefit from first-line chemotherapy, particularly with oxaliplatin, in 
comparison with wild-type patients. Alternatively the poor survival is driven by 
mechanisms mediating first-line chemotherapy resistance when 
superimposed on the BRAF-mutational landscape: supported by markedly 
worse post-progression survival independent of the delivery of second-line 
treatment, and the lack of PFS and OS deterioration in BRAF-mutant patients 
stable on first-line Ox/FP receiving chemotherapy-free breaks. The molecular 
basis for these observations requires study.   
 
Disappointing results of BRAF-inhibitors as single agents in aCRC[11] 
and a growing appreciation of molecular complexity of BRAF-mut aCRC[12] 
suggest that targeted approaches may require multi-agent combinations. 
Early clinical studies report encouraging clinical activity and acceptable 
toxicity with the combination of a BRAF-inhibitor, a MEK inhibitor and an anti-
EGFR agent.[27] These regimens are complex and likely to be expensive and 
will complement rather than replace chemotherapy.  
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This, the largest and most comprehensive analysis of chemotherapy 
outcomes in BRAF-mutant CRC patients provides new and important 
information with clinical relevance. In summary, BRAF-mutation confers a 
markedly worse prognosis independent of associated clinic-pathological 
features. Chemotherapy does provide meaningful improvements in outcome 
throughout treatment lines. Post-progression survival is markedly worse and 
vigilance is required to ensure the appropriate delivery of treatment after first- 
line progression. 
 
 
 
Legend to Figures and Tables 
 
Figure 1- Consort diagram of study participants from the FOCUS, COIN and 
PICCOLO trial 
 
Figure 2 –OS KM curves for BRAF-mut vs BRAF-wt for first line 
chemotherapy (FOCUS and COIN, all strategies) 
 
Figure 3 - Post-progression survival KM curves for BRAF-mut vs BRAF-wt 
following failure on first-line chemotherapy (COIN and FOCUS) 
 
Figure 4 – Overall survival KM curves for second line treatment, vs none in 
BRAF-mutant and wild-type patients 
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Table 1 – Patient characteristics by BRAF status 
 
Table 2 – Estimated crude HRs and 95% CIs for the effect of clinic-
pathological factors associated with BRAF on overall survival 
 
Table 3 - Estimated crude HRs and 95% CIs for the effect of BRAF-status 
(mutant vs wild-type) on PFS, P-PS and OS, then estimated crude ORs and 
95% CIs for the effect of BRAF-status (mutant vs wild-type) on RR and DCR 
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Figure 1 
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FOCUS - 1st line aCRC 
N = 2135 
 BRAF status available 
n=787 
 Strategy B 
5FU; IrFU or 
OxFU on prog 
n=371 
Strategy C 
IrFU or OxFU 
until prog 
n=357 
COIN - 1st line aCRC 
N = 2445 
  BRAF status available 
n=1946 * 
Arm A 
Cont. OxFp 
n=632 
Arm B 
Cont. OxFp   
plus 
Cetuximab 
n=662 
Arm C 
Intermittent       
OxFp 
n=652 
PICCOLO - 2nd line aCRC 
N = 1196 
  KRAS-mut 
BRAF available 
        n=477** 
      Ir 
    n=189 
      IrCs 
    n=288 
 KRAS-wt 
BRAF available 
n= 591** 
        Ir 
     n=270  
    IrPan 
    n=321 
 
 = Trial arm(s) included in RR, PFS, P-PS and OS analysis 
Strategy A 
5FU; Ir on 
prog 
n=59 
 IrFU 
N=183 
   OxFU 
N= 175 
5FU   = 5-fluorouracil 
Ir        = Irinotecan 
IrFU   = combination Ir + 5FU; OxFU = combination Ox + 5FU 
IrCs    = combination Ir + Ciclosporin 
IrPan  = combination Ir + Panitumumab 
OxFp  = combination of Oxaliplatin + free choice of 
               either 5FU (OxFU) or Capecitabine (OxCap) 
Cont.  = continuous 
Prog   = disease progression 
*         = BRAF status in 1284/1630 excluding arm B 
**       = BRAF status in 459/511 excluding IrCs & IrPan 
  = Trial arm(s) excluded from all analyses 
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Table 1 
 
 
1st line study population 
(FOCUS and COIN) 
(n=2071) 
2nd line study population 
(PICCOLO) 
(n=459) 
All patients 
 
BRAF-mut 
(n=191) 
BRAF-wt 
(n = 1880) 
p-
value** 
BRAF mut 
(n = 40) 
BRAF-wt 
(n = 419) 
p-
value** 
BRAF-mut 
(n=231) 
BRAF-wt 
(n=2299) 
p-
value** 
Median age (IQR) 63.4 ( 57-71) 
64 
(57-69)  
63.1 
(56-67) 
62.7 
(56-67)  
63.5 
(57.0-69.0) 
63.4 
(57.0-69.4)  
Sex n(%) 
Male 107 (56.0) 1271 (67.6) 
p=0.002 
13 (32.5) 295 (70.4) 
p<0.001 
120 (52.0) 1566 (68.1) 
p<0.001 Female 84 (44.0) 609 (32.4) 27 (67.5) 120 (28.7) 111 (48.0) 729 (31.7) 
Missing 0 (0.0) 0 (0.0) 0 (0.0) 4 (0.9) 0 4 (0.2) 
WHO PS 
n(%) 
0-1 
 
173 (90.6) 1750 (93.1) 
p=0.20 
39 (97.5) 393 (93.8) 
p=0.50* 
212 (91.8) 2143 (93.2) 
p=0.41 
2 18 (9.4) 130 (6.9) 1 (2.5) 26 (6.2) 19 (8.2) 156 (6.8) 
Resected 
primary n(%) 
Yes 131 (68.6) 1326 (70.5) 
p=0.91 
36 (90.0) 299 (71.3) 
p=0.01* 
167 (72.3) 1625 (70.7) 
p=0.34 No 50 (26.2) 496 (26.4) 4 (10.0) 118 (28.2) 54 (23.4) 614 (26.7) 
Missing 10 (5.2) 58 (3.1) 0 (0.0) 2 (0.5) 10 (4.3) 60 (2.6) 
Primary 
tumour 
location n(%) 
Right 111 (58.1) 451 (24.0) 
p<0.001 
22 (55.0) 126 (30.1) 
p=0.001 
133 (57.6) 577 (25.1) 
p<0.001 Left 70 (36.7) 1327 (70.6) 17 (42.5) 284 (67.8) 87 (37.6) 1611 (70.1) 
Missing 10 (5.2) 102 (5.4) 1 (2.5) 9 (2.1) 11 (4.8) 111 (4.8) 
Previous 
clinical 
benefit(%) 
Yes n/a n/a 
n/a 
21 (52.5) 271 (64.7) 
p=0.13 
21 (52.5) 271 (64.7) 
p=0.13 No n/a n/a 12 (30.0) 112 (26.7) 12 (30.0) 112 (26.7) 
Missing n/a n/a 7 (17.5) 36 (8.6) 7 (17.5) 36 (8.6) 
Peritoneal 
mets n(%) 
Yes 42 (22.0) 263 (14.0) 
p=0.003 
16 (40.0) 97 (23.2) 
p=0.02 
58 (25.1) 360 (15.7) 
p=0.001 No 148 (77.5) 1603 (85.3) 24 (60.0) 311 (74.2) 172 (74.5) 1914 (83.2) 
Missing 1 (0.5) 14 (0.7) 0 11 (2.6) 1 (0.4) 25 (1.1) 
Lung mets 
n(%) 
Yes 45 (23.6) 754 (40.1) 
p<0.001 
15 (37.5) 246 (58.7) 
p=0.006 
60 (26.0) 1000 (43.5) 
p<0.001 No 145 (75.9) 1112 (59.2) 25 (62.5) 164 (39.1) 170 (73.6) 1276 (55.5) 
Missing 1 (0.5) 14 (0.7) 0 (0.0) 9 (2.2) 1 (0.4) 23 (1.0) 
Liver mets 
n(%) 
Yes 129 (67.5) 1395 (74.2) 
p=0.04 
30 (75.0) 305 (72.8) 
p=0.89 
159 (68.8) 1700 (73.9) 
p=0.16 No 61 (31.9) 471 (25.1) 10 (25.0) 107 (25.5) 71 (30.8) 578 (25.1) 
Missing 1 (0.5) 14 (0.7) 0 (0.0) 7 (1.7) 1 (0.4) 21 (0.9) 
Nodal mets 
n(%) 
Yes 104 (54.5) 811 (43.1) 
p=0.003 
16 (40.0) 103 (24.6) 
p<0.001 
120 (52.0) 914 (39.8) 
P<0.001 No 86 (45.0) 1055 (56.1) 24 (60.0) 311 (74.2) 110 (47.6) 1366 (59.4) 
Missing 1 (0.5) 14 (0.7) 0 (0.0) 5 (1.2) 1 (0.4) 19 (0.8) 
MMR status 
n(%) 
dMMR 24 (12.6) 56 (3.0) 
p<0.001 
2 (5.0) 2 (0.5) 
0.03* 
26 (11.2) 58 (2.5) 
p<0.001 pMMR 143 (74.9) 1583 (84.2) 2 (5.0) 43 (10.3) 145 (62.8) 1626 (70.7) 
Missing 24 (12.6) 241 (12.8)) 36 (90.0) 374 (89.2) 60  (26.0) 615 (26.8) 
KRAS status 
n(%) 
WT 180 (94.2) 993 (52.8) 
p<0.001 
36 (90.0) 219 (52.3) 
p<0.001* 
216 (93.5) 1212 (52.7) 
p<0.001 Mut 8 (4.2) 857 (45.6) 0 (0.0) 172 (41.0) 8 (3.5) 1029 (44.8) 
Missing 3 (1.6) 30 (1.6) 4 (10.0) 28 (6.7) 7 (3.0) 58 (25.2) 
* Fishers exact test 
**Missing values excluded from comparisons 
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Table 2  
 
Prognostic marker Median 
survival (IQR) Comparison 
Unadjusted HR 
(95% CI) 
Adjusted HR** 
(95% CI) 
BRAF-mut 
191/2071 (9.2%) 10.8  (6.5-17.9) 
BRAF-mut vs 
wild-type 
n=2071, fail =1667 n=1608, fail = 1305 
1.69(1.44-1.99)p=<0.001 1.47 (1.21-1.78)p<0.001 
Poor PS* 
304/ 3765 (8.1%) 
 
9.0 (3.6-16.1) 
Poor vs good 
PS 
n=3765, fail =3086 n=1608, fail=1305 
1.81 (1.60-2.06), p<0.001 1.39 (1.12-1.73), p=0.003 
Plts >400 
639/3500 (18.2%) 
 
10.9 (5.9-18.6) High vs low plts 
n=3500,fail =2849 n=1608 ,fail=1305 
1.82 (1.65-1.99), p<0.001 1.57 (1.37-1.81),p<0.001 
Primary tumour in situ 
1303/ 3762 (34.6%) 
 
12.4 (6.8-20.3) 
Primary in situ 
vs resection 
n=3762, fail = 3086 n=1608, fail = 1305 
1.53 (1.42-1.64), p<0.001 1.45 (1.27-1.65),p<0.001 
Right PTL 
807/ 2982 (27.1%) 
 
12.8 (7.4-21.6) 
Right PTL vs 
left &rectal 
n=2982, fail=2445 n=1608, fail = 1305 
1.29 (1.18-1.41),p<0.001 1.17 (1.03-1.32),p=0.017 
dMMR 
134/ 2558 (5.2%) 
 
12.3 (6.5-21.2) 
dMMR vs 
pMMR 
n=2558, fail=2143 n=1608, fail=1305 
1.23 (1.02-1.49),p=0.030 1.17 (0.89-1.53), p=0.25 
peritoneal mets 
527/ 3717 (14.2%) 
 
11.7 (6.3-19.8) 
peritoneal mets 
vs no peritoneal 
mets 
n=3717, fail=3048 n=1608, fail=1305 
1.46 (1.32-1.61), p<0.001 1.29 (1.10-1.51),p=0.001 
*Poor PS is defined by WHO ≥2 
**All prognostic markers included in the multivariate analysis 
 
 
Table 3  
 
Clinical Endpoint Treatment strategy Median (IQR) survival (mo) Unadjusted HR (95% CI) 
Adjusted HR** 
(95% CI) BRAF-mut BRAF-wt 
PFS 
1st line OxFU or IrFU 
(FOCUS) 
n=32 n=325 n=357, fail =348 n=274, fail=266 
8.2 (3.6-10.3)) 8.8 (5.8-11.9) 1.09(0.76-1.58), p=0.63 1.07(0.69-1.67), p=0.75 
1st line OxFU 
(COIN) 
n=130 n=1154 n=1284,fail =1219 n=1009,fail=955 
5.7 (3.1-8.5) 6.3 (4.9-9.6) 1.20(0.99-1.45),p=0.057 1.14 (0.91-1.42),p=0.26 
P-PS 
1st line OxFU or IrFU 
(FOCUS) 
n=24 n=281 n=305, fail=268 n=266, fail = 247 
3.2 (1.5-10.7) 8.1 (4.3-15.9) 1.91 (1.25-2.91),p=0.003 1.65 (1.03-2.67),p=0.038 
1st line OxFU (COIN) n=102 n=970 n=1072, fail=829 n=836, fail=655 4.5(1.7-10.5) 9.6 (4.7-17.0) 2.00(1.61-2.49),p<0.001 1.64 (1.26-2.13),p<0.001 
OS 
All FOCUS strategies n=61 n=726 n=787, fail = 692 n=532, fail = 599 10.9 (7.7-17.7) 16.2 (9.5-25.2) 1.55 (1.18-2.04),p=0.030 1.44 (1.04-2.00),p=0.030 
1st line OxFU (COIN) n=130 n=1154 n=1284, fail = 975 n=1009 fail = 773 9.8 (6.2-17.9) 16.6 (9.7-27.5) 1.78 (1.46-2.17),p<0.001 1.51 (1.19-1.91),p<0.001 
Clinical Endpoint Treatment strategy RR / DCR (%) Unadjusted OR (95% CI) 
Adjusted OR** 
(95% CI) BRAF-mut BRAF-wt 
RR 
1st line OxFU or IrFU 
(FOCUS) 
n=32 n=325 n=357 n=274 
43.7% 43.1% 1.02 (0.49-2.13), p=0.94 1.09 (0.45-2.65),p=0.85 
1st line OxFp 
(COIN) 
n=130 n=1154 n=1284 n=1009 
34.3% 47.5% 0.52 (0.35-0.76),p=0.001 0.58 (0.37-0.92),p=0.020 
DCR 
1st line OxFU or IrFU 
(FOCUS) 
n=16 n=159 n=357 n=274 
68.9% 69.9% 0.95 (0.43-2.08), p=0.89 1.01 (0.36-2.84), p=0.97 
1st line OxFp 
(COIN) 
n=130 n=1154 n=1284 n=1009 
59.2% 72.0% 0.56 (0.39-0.82),p=0.003 0.76 (0.49-1.20),p=0.24 
HRs and ORs are for BRAF-mut versus BRAF-wt 
*excluding arm B 
** FOCUS and COIN adjusted for performance status, resection of primary tumour, PTL, baseline platelet count, peritoneal 
metastases and MSI status. PICCOLO adjusted for performance status, resection of primary tumour, PTL, peritoneal metastases 
and previous response to therapy. 
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